Clinical Trial: Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179783) titled 'Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)' on Sept. 08.

Brief Summary: This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).

Study Start Date: Sept. 22

Study Type: INTERVENTIONAL

Condition: Prostate Cancer (Adenocarcinoma) Prostate Cancer Metastatic Cas...